language of politics and has been able to use it to build a programme of basic research in the life sciences that, in quality and scope, is unrivalled.
The dramatic announcement last month that a team under Arthur Kornberg at Stanford had duplicated artificially the DNA found in the Phi 174 virus was the result of one of the research efforts Dr Shannon has supported. It is notable that the President of the United States, a man quite fluent in the language of politics, participated in the announcement of Kornberg's successful experiment.
Science was originally responsible only to the few. It now has to adapt itself to its new responsibilities to the many. This means that scientists, in medicine and other fields, must get into public affairs because public affairs are getting into science. This, I feel sure, is as true for Britain as it is for my country.
As scientists venture into public affairs, it might be useful to remember the constructive role they played when, just a few decades ago, they ventured into industry. The fear at that time, as has been pointed out, was that industry would lure science away from its historic mission of accumulating knowledge. This did not happen because the scientific fraternity persuaded industry to build a co-operative partnership with the universities, each partner doing that part of the job for which it was best suited. The universities, medical schools and hospitals remained committed to basic research, mainly by individual investigators. The pharmaceutical industry took on the major assignment of turning the results of this research into new tools of therapy. In order to do this effectively, company scientists established and maintained close working relationships with their academic peers and devoted a significant part of their time and effort to basic research, mostly of an interdisciplinary character. This new relationship strengthened both partners. Now a force even more powerful than industry has entered the picturethe taxpayer. Through government, he can insist on having his way. Using the power of the purse, government can undermine the roles of academic or pharmaceutical industry research, or both. Or, alternatively, the academic, scientific and medical fraternities can enter the public arena with their skills at persuasion and their enormous influence to steer this new force into constructive channels. If government can follow the earlier path outlined above, it will lead to a smooth-working partnership in which each partner is doing what he does best. The academic world, industry and government would each be strengthened by such a new relationship, and mankind would benefit from a new rate of progress toward the common goala healthier life for everyone. The incentive to do medical research stems from many quarters which -although united in purposeare nevertheless becoming more widely separated from one another in this era of specialized disciplines and organizations.
Had the early denizen of my home town, Theophrastus Bombastus Paracelsus, been asked who was responsible for medical research, he would undoubtedly have given a simple and straightforward answer, to wit: Medical research is my responsibility and that of my peers. And the position did not basically change until perhaps a century ago, when the special medical disciplines and all the basic medical sciences, including biochemistry, came of age. Meanwhile, the catalogue has become much longer since epidemiology, public health, population control, nutrition, radiobiology, genetics, and many other disciplines including aviation and space research have been added to the areas of scientific endeavour from which medical research takes its cues.
Today, medical research is not only the preoccupation of the medical schools and science faculties of universities, it has become a noble prerogative of private and public research institutes, of defence establishments, of national governments and international organizations, of charitable institutions and foundations, and, last but not least, ofa highly developed pharmaceutical industry whose livelihood depends almost entirely on medical research.
But let me return to the question: Whose responsibility is medical research? And another question which follows logically: To whom are those engaged in medical research responsible?
The latter question is easy to answer. Since all research costs money, those who carry out research are responsible to those who finance it: the government agencies, the international organizations, the private foundations, the university administrations, the industrial managements, the stockholders and the taxpayers.
In evaluating the research for which they are paying, the donors will of course consider the degree of excellence of the work performed. But in medical research there enters a second consideration which would not apply in, say, mathematical research. It is the usefulness of the results.
By definition, medicine is an applied science or, better, is an application of science to the art of medicine. It is expected to produce results which, over and above the accumulation of knowledge, should turn out to be directly beneficial to man. While this may not always be openly acknowledged, it is nevertheless a fact. And it is likewise a fact that money is much easier to obtain from government, from charities, and from industrial managements for research which promises practical results. There is an old story which illustrates this point. As long as it was called the National Institute of Microbiology, this branch of the US National Institutes of Health always had a great deal of trouble getting their yearly budgets approved by Congress. It is said that one day, at a hearing, a congressman asked: 'Why do you need all this money? I never heard of anyone dying of microbiology.' Whereupon the Institute quickly changed its name to 'National Institute of Allergy and Infectious Diseases', and from then on the cash would roll in much more easily.
We should note, then, that most medical research is goal-directed. It should produce results providing better understanding of physiopathological processes, improved diagnostic techniques, more effective therapy, better prophylactic measures, in short, it should alleviate the burden of sickness and provide the basis for longer and happier lives. This is what society expects from medical research. The varying nature of the research goals mentioned may determine the institutions where the research is best carried out, which leads back to the first question: Whose responsibility is medical research?
We need not discuss here whether medical research is necessary or not. Sir John McMichael has answered this question unequivocally two years ago at a similar conference here in London (McMichael 1967) . Medical research is necessary and will never end. But the responsibilities for carrying it out are divided amongst those qualified and equipped to do it.
Epidemiology and preventive medicine appear to be the primary responsibility of governmental institutions such as Ministries of Health or Public Health Services, and of international bodies such as the World Health Organization. The purpose of this research is the improvement of the collective state of health of populations and their protection from damaging environmental agents. This sort of work is based on large numbers of observations on large numbers of people often distributed over wide geographical areas. It requires substantial funds, many collaborators, and large organizations. The excellent BCG trials carried out by the Medical Research Council in the United Kingdom, the Framingham Study in the United States, and the current investigations into the consequences of cigarette smoking are investigations of this kind.
The research devotedto obtaining basic information on the pathophysiological disease processes, on their recognition and perhaps their cure has traditionally been the task of universities and medical research institutes. Personally I feel that the university is the best place for academic research and if more research institutes find their way into closer associations with universities it will be to the mutual benefit of both.
By their very nature and the economic basis on which they are founded, the research laboratories of the pharmaceutical industry are predestined to assume the primary responsibility for that part of therapeutic research which, in the widest context of the term, may be called chemotherapy. It is an uncontested fact that over the past fifty years the bulk of our chemotherapeutic armamentarium, the large majority of all effective modern drugs, has emerged from the laboratories of the pharmaceutical industry around the world. It is also a matter of record that nowadays these laboratories are probably the only ones geared to perform the demanding and sophisticated development work which an active chemical compound must undergo in order to become a useful drug.
Finally, the main responsibility of the foundations and charitable funds may be seen in financing research projects which, by their very nature, do not really fit into any of the three aforementioned categories, or in supporting scientists who deserve to be given an opportunity to prove themselves, but who, for one reason or another, present too great a risk to be readily supported by government or industry. Private foundations being accountable only to themselves and not to the public can afford to take greater chances than is possible for official agencies or industrial managements. Moreover, the total funds which are at the disposal of private foundations are so small in comparison to the enormous amounts of money spent by government and industry that in order to preserve their identity and their creativeness as donors the foundations should choose different and somewhat unorthodox objectives for their munificence. Also they are unhampered by administrative red tape and therefore free to give quickly wherever the need is greatest.
Having thus tried to separate the various subjects of medical research by their nature and to allocate certain areas to certain sponsors, I must now hasten to say that such separation is highly artificial and unrealistic. Research in the life sciences is an indivisible whole and seemingly unrelated results may suddenly become meaningful in a different context. Chance observations and their intelligent pursuit are still one of the main sources of real progress.
The scientific community is a tightly knit, interdependent group. The more freely it communicates and the more closely it co-operates, the better it is for all concerned. I consider it a very happy state of affairs that in some countries, such as Switzerland and the United States, there exists a free and open communication and collaboration between the universities, the government institutions and industry. This open-door policy has proven highly fruitful and profitable for all concerned. It permits the universities to make use for their teaching and research of the large pool of talent, know-how and the material resources which the industries and government possess. And it allows the industrial research laboratories to partake of the manifold opportunities which the academic community has to offer. Wherever universities and research-based industries have found one another, they have developed real symbioses where, as in any true symbiosis, it is no longer possible to decide whether a partner is giving more than he takes. My own home town, Basle, is a case in point, but there are many more, and such happy relationships are by no means restricted to the life sciences.
To an outsider, it seems rather a pity that in some other countries similar conditions do not seem to prevail and it is not difficult to see why more intimate and fruitful associations have so far failed to develop there. On the side of the industries, the failure is due to regrettable oversecrecy, and on the academic side to a certain aloofness which looks down at what they call applied research. For both attitudes there seems no place left in our time. The application of science has moulded the world in which we live and it will continue to do so. Should the university fail to assume a more active part in this exciting enterprise, it would simply become an odd curiosity, an ivory tower on a desert island. And should industry fail to understand that it is no longer feasible to lock up secrets for any length of time in closely guarded laboratories, or to isolate industrial scientists from the rest of the scientific community, it would soon lose all its good scientists and be left behind with stale and worthless secrets.
Any government that tolerates the mere coexistence of universities and industries without actively prodding them into close co-operation is permitting to lie fallow a rich potential of scientific possibilities to the detriment of the country's academic future and of its industrial development.
In order to play their part in medical research the universities must be adequately financed by public funds and the industries must be able to thrive on a sound economic basis, since, in contrast to all other institutions, they must provide their research funds from their own earnings. From the financial point of view, pharmaceutical research is a long-term investment. It takes an average of something like five to seven years of developmental work for a new drug to pass all the rigid tests which are required before it can be marketed. Most experimental drugs never reach this stage, and some which do never become profitable, because the diseases they cure are rare, or because the patients who need these drugs are poor people from poor countries that just cannot provide such elementary items as food for the hungry and medicines for the sick. But without a reasonable relationship between research investment and over-all profit the industry can no longer afford the heavy research expenses, and it is the few successful drugs which must finance the entire expensive establishment.
As we are all aware, the pharmaceutical industry today is under heavy attack all over the world. Mostly these attacks are politically motivated although some serious criticisms emerge also from the medical world. This is not the place to enter into a discussion on this subject. Suffice it to say that should these attacks continue to become more vicious and be followed by political actions seriously menacing the economic basis of the pharmaceutical industry, the resulting losses would not only affect the industries themselves, the hundreds of thousands of people whom they support and the countries where they pay taxes and from which they export, but also the basic medical sciences as well as medical therapy to which the pharmaceutical industry has made continuing and significant contributions almost since its very beginning.
It is often said that basic research is the task of academic institutions, whereas industrial laboratories are the realm of applied research. Frankly, I do not like this distinction. First of all, I have not found a satisfactory definition of what is basic and what is applied medical research. As I mentioned before, all medical research hasby definitionpractical implications, simply because its results may sooner or later be applied to medicine, i.e. to the prevention of illness and to the art of healing the sick. Take the work of Pasteur. I would be at a loss trying to determine whether it is more outstanding for its contributions to our basic knowledge of the characteristics of the living cell or for the benefits that preventive as well as curative medicine were able to draw from it. Or take the antibiotics. Their therapeutic value is obvious, but they were of at least equal significance to the progress of molecular biology and modern genetics. Some of them, like actinomycin and puromycin, have no place in therapy, but they became indispensable scientific tools. The same is true of aldosterone, which was synthesized in our laboratories and for which no therapeutic use has yet been found. Or take the beautiful piece of work on interferon induction by double-stranded RNA, which has just been published from Dr Tishler's laboratory and which is probably still far away from practical usefulness (Lampson et al. 1967) . Antibiotics and steroids are excellent examples of the fruitful cross-fertilization which may occur between academic and industrial research and it would be an idle task trying to decide which of the many steps leading to the end result were basic and which were applied.
To summarize, medical research is the responsibility of the entire community of life scientists. Their work is financed by government, industry and private charities. Certain areas of research are primarily incumbent on each of these groups according to their resources and the nature of the problem; but the entire and, despite all the progress, still formidable task must be tackled by a concentrated and integrated effort of all who are qualified to contribute.
Let me in conclusion touch upon two points which have some bearing on our subject. The one concerns medical research in developing countries. These countries have a tremendous need for medical research intelligently applied to their problems. The problems are highly specific for these countries, not so much by their medical and scientific nature, but by the socio-economic context in which they present themselves. It seems an urgent task worthy of the very best brains of these countries to work on the solution of their problems in their own way, i.e. with their own people, in their own countries and with their own methods. This is the only way in which they can be solved. In many far away places, Britain has done excellent work by creating local institutions of learning and research and by training people on the spot to tackle their difficult tasks with modern scientific methods. This approach seems much more successful than training large numbers of scientists from developing countries in Europe or America and then sending them back after many years during which they have become spoiled and estranged from their own culture.
The second point concerns the consequences for our society of the advances of medical research: the population explosion; the overageing of our population; the survival of an everincreasing number of creatures whose life can only be preserved by complicated technical devices; the yet unknown dangers resulting from the wide use of powerful and specifically acting drugs; and the challenge to physical and mental health resulting from a technical environment which is rapidly changing our world into a new, unnatural habitat of man. I omit from this enumeration the even more frightening aspects of technical progress which today are still in the realm of science fiction, but which tomorrow already will be hard realities: the possibility to tamper with the genetic makeup, to influence at will man's personality and character, and other like prospects denoting the increasing power of medical science.
Only occasionally and in a random fashion are life scientists today concerned with these consequences of their own endeavour. I suggest that they can no longer shun the obligation to become involved and that this aspect of medical research is the responsibility of all those who by their own successful research actively contribute to the very creation of these problems.
